XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented
at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.
This study is aimed at establishing the efficacy and safety of the combination
cetuximab/XELOX as first line therapy in patients with MCRC.